Claims
- 1. A compound of the formula ##STR467## including pharmaceutically acceptable salts thereof; wherein M is oxygen or sulfur;
- Y is --CH.sub.2 --, --NH-- or --O--; ##STR468## is R.sub.1, R.sub.1 ', R.sub.2, R.sub.2 ', R.sub.12, R.sub.13 and R.sub.14 are independently selected from hydrogen, alkyl, arylalkyl, aryl, heteroaryl and cycloalkyl;
- Z and Z' are independently selected from a single bond ##STR469## R.sub.3 and R.sub.5 are independently selected from hydrogen, lower alkyl, halo substituted lower alkyl, --(CH.sub.2).sub.n --aryl, --(CH.sub.2).sub.n --heterocyclo, ##STR470## and --(CH.sub.2).sub.n --cycloalkyl; R.sub.4 is selected from hydrogen, lower alkyl, halo substituted lower alkyl, --(CH.sub.2).sub.n --aryl, --(CH.sub.2).sub.n --heterocyclo, --(CH.sub.2).sub.n --OH, --(CH.sub.2).sub.n --O--lower alkyl, --(CH.sub.2).sub.n --NH.sub.2, --(CH.sub.2).sub.n --SH, --(CH.sub.2).sub.n --S--lower alkyl, --(CH.sub.2).sub.n --O--(CH.sub.2).sub.g --OH, --(CH.sub.2).sub.n --O--(CH.sub.2).sub.g --NH.sub.2, ##STR471## n is an integer from 1 to 5; g is an integer from 2 to 5;
- R.sub.7 is ##STR472## R.sub.8 is 2,4-dinitrophenyl, ##STR473## R.sub.9 is hydrogen, lower alkyl, ##STR474##
- 2. A compound in accordance with claim 1 wherein
- R.sub.3 is straight or branched chain lower alkyl of 3 to 5 carbons, --(CH.sub.2).sub.n --cyclopentyl, --(CH.sub.2).sub.n --cyclohexyl ##STR475## wherein n is an integer from 1 to 3; R.sub.4 is hydrogen, straight or branched chain lower alkyl of up to 5 carbons, ##STR476## wherein n is an integer from 1 to 3;
- R.sub.5 is straight or branched chain lower alkyl of up to 5 carbons, ##STR477##
- 3. A compound in accordance with claim 1 wherein
- when r is one, X--Y-- is ##STR478## when r is zero, X--Y-- is ##STR479## R.sub.1 and R.sub.2 are independently selected from hydrogen, ##STR480##
- 4. A compound of claim 1 wherein
- M, Z and Z' are each oxygen;
- R.sub.1 and R.sub.2 are each methyl; ##STR481## R.sub.5 is benzyl; r is one;
- Y is --NH--; and ##STR482##
- 5. A composition for treating hypertension in a mammalian species comprising a pharmaceutically acceptable carrier and an anti-hypertensively effective amount of a compound of claim 1.
- 6. A method of treating hypertension in a mammalian species which comprises administering an anti-hypertensively effective amount of the composition of claim 5.
Parent Case Info
This is a continuation-in-part of U.S. Ser. No. 317,257 filed Feb. 28, 1989 and now abandoned, which is a continuation-in-part of U.S. Ser. No. 163,593 filed Mar. 3, 1988 and now abandoned.
Foreign Referenced Citations (9)
Number |
Date |
Country |
5288186 |
Jan 1986 |
AUX |
0103867 |
Sep 1983 |
EPX |
0104041 |
Mar 1984 |
EPX |
0190891 |
Aug 1986 |
EPX |
0249445 |
Jun 1987 |
EPX |
0266950 |
Oct 1987 |
EPX |
3825242 |
Feb 1989 |
DEX |
201036 |
Sep 1984 |
JPX |
WO9009172 |
Feb 1989 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Chemical Abstracts, vol. 98, p. 646 (72259n) (1983). |
Organometallics, vol. 90, p. 527 (72285c) (1979). |
Powers et al., "Inhibition of Human Leukoctye Elastase, Porcine Pancreatic Elastase and Cathepsin G by Peptide Ketones", Proceedings from 9th American Peptide Symposium, Jun. 23-28, 1985, Univ. of Toronto, Canada. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
317257 |
Feb 1989 |
|
Parent |
163593 |
Mar 1988 |
|